Insights

Innovative Technologies AQEMIA leverages cutting-edge physics-based generative AI and quantum-inspired machine learning to accelerate drug discovery, presenting opportunities to partner with biotech firms seeking advanced AI-driven research solutions.

Funding & Growth With over 100 million USD in cumulative funding and recent office expansion to London, AQEMIA demonstrates strong financial backing and infrastructure development, indicating a readiness for strategic collaborations and investment opportunities.

Rapid Industry Engagement Active participation in major healthcare and technology conferences signifies AQEMIA’s drive to stay at the forefront of biotech innovation, offering avenues for thought leadership collaborations and networking with industry stakeholders.

Market Positioning As part of the French Tech 120 and a member of prominent biotech associations, AQEMIA is well-positioned to attract partnerships with multinational pharmaceutical companies seeking novel drug discovery platforms.

Therapeutic Focus Specializing in oncology and therapeutic molecule design via AI and physics-based modeling, AQEMIA provides tailored solutions for pharma companies focusing on targeted therapies and precision medicine development.

AQEMIA (AI x Drug Discovery) Tech Stack

AQEMIA (AI x Drug Discovery) uses 8 technology products and services including Amazon EC2, Kustomize, GitLab CI, and more. Explore AQEMIA (AI x Drug Discovery)'s tech stack below.

Amazon EC2

Cloud Infrastructure Computing

Kustomize

Configuration Management

GitLab CI

Continuous Integration

GROMACS

Data Management

Google Cloud Platform

Infrastructure As A Service

GitLab

Issue Trackers

Google Tag Manager

Tag Management

FastAPI

Web Frameworks

AQEMIA (AI x Drug Discovery) Email Formats	Example	Percentage
First.Last@aqemia.com	John.Doe@aqemia.com	97%
First.Middle@aqemia.com	John.Michael@aqemia.com	2%
First@aqemia.com	John@aqemia.com	1%

AQEMIA (AI x Drug Discovery) Email Formats

Example

Percentage

First.Last@aqemia.com

John.Doe@aqemia.com

97%

First.Middle@aqemia.com

John.Michael@aqemia.com

First@aqemia.com

John@aqemia.com

Frequently Asked Questions

Where is AQEMIA (AI x Drug Discovery)'s headquarters located?

AQEMIA (AI x Drug Discovery)'s main headquarters is located at 1 Boulevard Pasteur Paris, Île-de-france 75015 France. The company has employees across 3 continents, including EuropeAfricaNorth America.

What is AQEMIA (AI x Drug Discovery)'s official website and social media links?

AQEMIA (AI x Drug Discovery)'s official website is aqemia.com and has social profiles on LinkedIn Crunchbase.

What is AQEMIA (AI x Drug Discovery)'s SIC code NAICS code?

AQEMIA (AI x Drug Discovery)'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AQEMIA (AI x Drug Discovery) have currently?

As of June 2026, AQEMIA (AI x Drug Discovery) has approximately 85 employees across 3 continents, including EuropeAfricaNorth America. Key team members include Ceo & Co-Founder: M. L.Ceo And Co-Founder: M. L.Coo And Co-Founder: E. M. R.. Explore AQEMIA (AI x Drug Discovery)'s employee directory with LeadIQ.

What industry does AQEMIA (AI x Drug Discovery) belong to?

AQEMIA (AI x Drug Discovery) operates in the Biotechnology Research industry.

What technology does AQEMIA (AI x Drug Discovery) use?

AQEMIA (AI x Drug Discovery)'s tech stack includes Amazon EC2KustomizeGitLab CIGROMACSGoogle Cloud PlatformGitLabGoogle Tag ManagerFastAPI.

What is AQEMIA (AI x Drug Discovery)'s email format?

AQEMIA (AI x Drug Discovery)'s email format typically follows the pattern of First.Last@aqemia.com. Find more AQEMIA (AI x Drug Discovery) email formats with LeadIQ.

How much funding has AQEMIA (AI x Drug Discovery) raised to date?

As of June 2026, AQEMIA (AI x Drug Discovery) has raised $7.4M in funding. The last funding round occurred on Apr 01, 2025 for $7.4M.

When was AQEMIA (AI x Drug Discovery) founded?

AQEMIA (AI x Drug Discovery) was founded in 2019.

AQEMIA (AI x Drug Discovery)

Q: How many employees does AQEMIA (AI x Drug Discovery) have currently?

AQEMIA (AI x Drug Discovery) has approximately 85 employees.

Q: What technology does AQEMIA (AI x Drug Discovery) use?

AQEMIA (AI x Drug Discovery)'s tech stack includes Grafana, Cloudflare, AWS CloudFormation, Amazon S3, C++.

Q: What is AQEMIA (AI x Drug Discovery)'s NAICS code?

AQEMIA (AI x Drug Discovery)'s NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchÎle-de-france, France51-200 Employees

AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data.

We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization.

AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. 

AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London.

AQEMIA is based in Paris (HQ) and London.

We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com

Discover the roles and behind-the-scenes at AQEMIA: https://www.welcometothejungle.com/fr/companies/aqemia

Insights

Similar companies to AQEMIA (AI x Drug Discovery)

SkinCeuticals

Dermalogica

iS CLINICAL

Eminence Organic Skin Care

IMAGE Skincare

Jan Marini Skin Research

Murad

PCA SKIN